Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

/p>

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Healthcare

Jenny Moede

Senior Vice President

(503) 443-7000

jmoede@wagged.com

-FINANCIAL TABLES FOLLOW-

TRUBION PHARMACEUTICALS. INC.

STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue $4,635 $16,539 $14,450 $30,175

Operating expenses:

Research and development 8,877 9,570 28,201 23,451

General and administrative 2,578 2,032 7,652 7,101

Total operating expenses 11,455 11,602 35,853 30,552

Income (loss) from operations (6,820) 4,937 (21,403) (377)

Interest income 1,120 419 3,582 1,389

Interest expense (213) (49) (566) (163)

Other income - 83 - 22

Net income (loss) $(5,913) $5,390 $(18,387) $871

Basic net income (loss) per share $(0.33) $3.79 $(1.04) $0.63

Diluted net income (loss) per share $(0.33) $0.40 $(1.04) $0.06

Shares used in computation of basic

net income (loss) per share 17,758 1,421 17,654 1,376

Shares used in computation of diluted

net income (loss) per share 17,758 13,245
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... OH (PRWEB) January 22, 2015 Crystal Diagnostics ... today that it has received AOAC-PTM Certifications for the six ... O121, and O145; collectively referred to as STEC or the ... 1 colony forming unit (cfu) per 325 g of raw ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... July 7 Silence Therapeutics plc (AIM: SLN) ... United States patent 7,750,144, titled Methods and Compositions ... the United States Patent and Trademark Office (USPTO).  The ... (RNAi) agents having decreased off-target silencing activity through certain ...
... development of future molecular devices, new display technologies, and ... to play a primary role. ... interlocked structures that consist of a dumbell-shaped molecule whose ... behave as molecular "machines," with the ring moving along ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
Cached Biology Technology:Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 2Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 3Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 4Study measures single-molecule machines in action 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... N.M., Feb. 19, 2013A study by researchers from Los Alamos ... direct-acting antiviral agent in development for the treatment of hepatitis ... the fastest viral decline ever seen with anti-HCV drugs ... C virus affects about 150 million people worldwide. It is ...
... and higher education institutions is developing a network for ... help doctors to diagnose different types of possible cancerous ... The seven partners across four European countries, Spain, ... project, known as BIOPOOL, with a budget of 2,500,000 ...
... PARK, Pa. Identifying areas of malarial infection ... on the average monthly temperatures, according to a ... may also apply to environmentally temperature-dependent organisms other ... key driver of several of the essential mosquito ...
Cached Biology News:Computer modeling reveals how surprisingly potent hepatitis C drug works 2Data pooling in biobanks: The BIOPOOL project 2New approach alters malaria maps 2
...
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
Biology Products: